Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Scientists could build better drugs by learning from bacteria-derived molecules

Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.

19 Jun 2018

Novel compound as effective as FDA-approved antibiotics for treating deadly infections

Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.

18 Jun 2018

UC San Diego establishes new Center For Anti-Parasitic Drug Discovery And Development

Neglected tropical diseases are a group of chronic and disabling parasitic infections that primarily affect poor and underserved communities.

14 Jun 2018

Unique project to develop fully-automated technology for faster and effective drug discovery

A unique project to develop technology to drive fast and effective drug discovery was announced today by Business Secretary Greg Clark. Based at the Rosalind Franklin Institute in Harwell, Oxfordshire, this new project will pioneer fully-automated hands-free molecular discovery to produce new drugs up to ten times faster and transform the UK’s pharmaceutical industry.

13 Jun 2018

New method can quickly and accurately detect infections

A new study by Waldemar Gorski, professor and chair of the UTSA Department of Chemistry, and Stanton McHardy, associate professor of research in chemistry and director of the UTSA Center for Innovative Drug Discovery, describes a method that could show quickly and accurately whether a person has been infected with harmful bacteria or other pathogens.

12 Jun 2018

Scientists find novel tactic with potential for fighting medulloblastoma

Scientists have a new tactic with potential for fighting medulloblastoma, the most common and most aggressive form of brain tumor in children. The results are scheduled for publication in Cancer Cell.

12 Jun 2018

Tradeshow Talks with Porvair Sciences

We will be featuring our latest automation-ready nitrogen blowdown evaporator, the Ultravap Mistral and our new electronic cap mat applicators at ACHEMA 2018.

From Porvair Sciences Limited 11 Jun 2018

International experts agree on need for human-relevant research to improve drug discovery

The average pre-approval cost of research and development for a successful drug is estimated to be US$2.6 billion and the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950.

8 Jun 2018

Regeneron collaborates with Zoetis to research antibody therapies for animals

Regeneron Pharmaceuticals, Inc. and Zoetis Inc. today announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover new veterinary treatments.

6 Jun 2018

Zebrafish may hold answers to how tumors develop in childhood muscle cancer

A popular aquarium fish may hold answers to how tumors form in a childhood cancer.

6 Jun 2018

Cloud Pharmaceuticals enters into drug discovery collaboration with GSK

Cloud Pharmaceuticals, Inc., an Artificial Intelligence-driven drug design and development company, announced today they have entered into drug discovery collaboration with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified targets.

31 May 2018

New 3D brain organoid may hold potential in drug discovery, disease modeling

Wake Forest Institute for Regenerative Medicine scientists have developed a 3D brain organoid that could have potential applications in drug discovery and disease modeling.

30 May 2018

Novoheart announces next generation of 'Human heart-in-a-jar' technology for advanced drug discovery

Novoheart today announced that the next generation of its ‘Human heart-in-a-jar’ technology - which makes up a key component of its comprehensive MyHeartTM Platform - will be unveiled for the first time at the Annual Meeting of the International Society for Stem Cell Research, held in Melbourne, Australia from 20-23 June, 2018.

26 May 2018

Neurological protein found to protect against inflammatory diseases

Researchers have identified a protein involved in the activation of macrophages that protects against inflammatory disorders such as sepsis and inflammatory bowel disease.

21 May 2018

Developing a High Throughput Mass Spectrometry Platform for Drug Discovery

Prof. Jonathan Wingfield, AstraZeneca, describes the collaboration with Labcyte and Waters to develop a high throughput mass spectrometry platform.

From Pittcon 18 May 2018

AstraZeneca collaborates with Emulate to integrate Organs-on-Chips technology into drug development labs

Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.

From AstraZeneca 17 May 2018

Researcher develops small molecules that inhibit derailment of gene expression in cancer

Not everyone person who has a "cancer gene" will inevitably develop this disease in their lifetime. Thanks to a new area of research called epigenetics, we now know that many genes are only read under certain circumstances.

17 May 2018

FDA allows KU Medical Center to begin clinical trial of novel cellular therapy for HR/SR aGvHD

The University of Kansas Medical Center announced that the U.S. Food and Drug Administration has cleared it to begin a first-in-human clinical trial of MSCTC-0010 in patients with de novo high-risk acute or steroid-refractory acute graft-versus-host disease (HR/SR aGvHD).

16 May 2018

Emulate partners with AstraZeneca to accelerate development of Organs-on-Chips technology

Emulate, Inc. has formed a collaborative partnership with AstraZeneca's Innovative Medicines and Early Development Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.